Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by an educational grant from GlaxoSmithKline.
“D” is for Diagnosis® - Cracking the Case in Rare Disorders with Respiratory Symptoms: Practical Approaches to Identification and Clinical Management
Release Date: October 25, 2021
Expiration Date: October 25, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze the underlying pathogenesis of eosinophilic disorders
- Develop a differential diagnosis for management of patients with eosinophilic disorders
- Apply efficacy and safety data for emerging therapies for patients with eosinophilic disorders
- Implement evidence-based guidelines in managing patients with eosinophilic disorders
Faculty, Staff, and Plannrs’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
Program Chair
Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
Director, NJH Cohen Family Asthma Institute
National Jewish Health
Denver, CO
Disclosures: Grant Research Support: Sanofi, AstraZeneca, Teva; Consultant: AstraZeneca, Amgen, GlaxoSmithKline, Sanofi, Genzyme, Regeneron, Boehringer Ingelheim, Novartis, Genentech, Pulmatrix, Teva, Equillium, CytoReason, resTORbio, Cohero Health, Cerecor, Incyte, Sound Biologics, Kinaset Therapeutics.
Faculty
Associate Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
University of California San Diego Health
San Diego, CA
Disclosures: Grant/Research Support: AstraZeneca, GlaxoSmithKline, Regeneron; Consultant: AstraZeneca, GlaxoSmithKline.
Clinical Associate Professor
Division of Allergy and Clinical Immunology
Department of Internal Medicine
University of Michigan Health
Ann Arbor, MI
Disclosures: Grant/Research Support: NATRON study, AstraZeneca, official site (University of Michigan); Consultant: GlaxoSmithKline.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
